Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Neurocrine Biosciences (NBIX) over the last 15 years, with Q4 2025 value amounting to $58.6 million.

  • Neurocrine Biosciences' Share-based Compensation fell 1174.7% to $58.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $217.9 million, marking a year-over-year increase of 1145.78%. This contributed to the annual value of $217.9 million for FY2025, which is 1145.78% up from last year.
  • Neurocrine Biosciences' Share-based Compensation amounted to $58.6 million in Q4 2025, which was down 1174.7% from $53.7 million recorded in Q3 2025.
  • Neurocrine Biosciences' Share-based Compensation's 5-year high stood at $68.5 million during Q2 2023, with a 5-year trough of $32.9 million in Q1 2021.
  • Moreover, its 4-year median value for Share-based Compensation was $47.8 million (2023), whereas its average is $49.3 million.
  • Examining YoY changes over the last 5 years, Neurocrine Biosciences' Share-based Compensation showed a top increase of 7427.82% in 2024 and a maximum decrease of 3708.03% in 2024.
  • Neurocrine Biosciences' Share-based Compensation (Quarter) stood at $32.9 million in 2021, then rose by 15.81% to $38.1 million in 2023, then soared by 74.28% to $66.4 million in 2024, then decreased by 11.75% to $58.6 million in 2025.
  • Its Share-based Compensation was $58.6 million in Q4 2025, compared to $53.7 million in Q3 2025 and $52.8 million in Q2 2025.